RBC Capital Maintains Outperform on Sarepta Therapeutics, Lowers Price Target to $151
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams has maintained an Outperform rating on Sarepta Therapeutics (NASDAQ:SRPT) but has reduced the price target from $155 to $151.

January 25, 2024 | 4:43 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
RBC Capital analyst reaffirms Outperform rating on Sarepta Therapeutics but lowers price target to $151 from $155.
The reduction in price target by RBC Capital may cause some investors to adjust their valuation models, potentially leading to a short-term negative sentiment. However, the maintenance of an Outperform rating suggests that the analyst still sees positive fundamentals in the company, which could balance out the impact on the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100